As the productivity imperative looms ever-larger, companies need to rethink their strategic options and put productivity at the heart of any upcoming change programme or improvement agenda. Pricing and volume expansion is losing its appeal; advances in technology and analytics are opening the door to new, energetic non-pharma disruptors; and the threat of disintermediation in terms of data and patient engagement has become increasingly significant. Pharma’s R&D and commercial models are under pressure. There’s a problem. But, what’s the solution? Some say that fundamental changes are needed at the human level. Hire better and smarter people and retain them is the new mantra.
Martin Lush Global Vice President, Pharma Biotech and Medical Devices, NSF Health Sciences
Christoph Heinemann Vice President Strategy & Business Management, Global Biologics, Sanofi
Andy Evans Site Lead (Vice President), Macclesfield Multi Format Facility, AstraZeneca
Sean Bermingham Head of Formulated Products, Process Systems Enterprise (PSE)
Stefan Egli, Vice President, Head of Global Strategic Accounts, Process Solutions, Merck